Compare Fubotv Inc (FUBO) vs 10X Genomics Inc (TXG) Price & Performance

FUBO trades at $9.54, down 2.95% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $172.25 million in 2024, but revenue grew to $1.62 billion, and profitability improved significantly in 2025 with a net income margin of 7.61%. Valuation ratios appear low, with a P/E of 2.67 and P/S of 0.21. Recent news highlights the appointment of a new CEO from Disney, sparking investor optimism about future growth.

The outlook is mixed; low valuations and a path to profitability present opportunity, but persistent cash flow challenges and high debt levels pose significant risks. Analyst consensus is a Buy with a $16.25 price target, suggesting substantial upside if the new leadership can execute on growth and monetization strategies effectively.

TXG is trading at $45.80, up 9.65% today, showing strong momentum despite mixed analyst sentiment. The stock exhibits bullish technical signals with positive moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company continues to report revenue growth with improving margins, narrowing losses from -$166M in 2022 to -$44M in 2025. Recent developments include strategic acquisitions and research collaborations that strengthen its life sciences technology position.

The outlook remains cautiously optimistic as TXG demonstrates operational improvement and strategic positioning in genomics technology. Key opportunities include continued margin expansion and platform adoption, while risks involve persistent profitability challenges and competitive pressures. Analyst consensus shows divided opinions with a $37.71 price target below current levels, suggesting potential near-term volatility despite long-term growth prospects.